Similar articles

• KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.

  Lahti SJ, Xing M, Zhang D, Lee JJ, Magnetta MJ, Kim HS. Lahti SJ, et al. J Vasc Interv Radiol. 2015 Aug;26(8):1102-11. doi: 10.1016/j.jvir.2015.05.032. J Vasc Interv Radiol. 2015. PMID: 26210240 Clinical Trial.
• Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.

  Türk G, Eldem G, Kılıçkap S, Bozkurt FM, Salancı BV, Çil BE, Peynircioğlu B, Yalçın Ş, Balkancı F. Türk G, et al. J Gastrointest Cancer. 2019 Jun;50(2):236-243. doi: 10.1007/s12029-018-0053-z. J Gastrointest Cancer. 2019. PMID: 29354877
• Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with ⁹⁰Y Radioembolization.

  Narsinh KH, Van Buskirk M, Kennedy AS, Suhail M, Alsaikhan N, Hoh CK, Thurston K, Minocha J, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA, Rose SC. Narsinh KH, et al. Radiology. 2017 Jan;282(1):281-288. doi: 10.1148/radiol.2016152100. Epub 2016 Jul 19. Radiology. 2017. PMID: 27440733 Free PMC article.
• Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.

  Kennedy AS, Salem R. Kennedy AS, et al. Cancer J. 2010 Mar-Apr;16(2):163-75. doi: 10.1097/PPO.0b013e3181d7e8cf. Cancer J. 2010. PMID: 20404614 Review.
• Angiogenesis in ⁹⁰Y-Radioembolization of Colorectal Liver Metastases.

  Alsultan AA, Barentsz MW, Smits MLJ, Koopman M, Lam MGEH, Rosenbaum CENM. Alsultan AA, et al. Semin Nucl Med. 2019 May;49(3):204-210. doi: 10.1053/j.semnuclmed.2019.01.004. Epub 2019 Jan 31. Semin Nucl Med. 2019. PMID: 30954186 Review.